CARTITUDE Trials in Multiple Myeloma
Experts discussed safety and efficacy data of cilta-cel for R/R MM from the CARTITUDE-1 and CARTITUDE-2 studies.
Investigational Agents in Relapsed/Refractory Myeloma
Experts discuss emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.
Using CAR T Therapy in R/R Multiple Myeloma
Nina Shah, MD, and other experts discuss the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.